The role of glycans in the development and progression of prostate cancer

@article{Munkley2016TheRO,
  title={The role of glycans in the development and progression of prostate cancer},
  author={Jennifer Munkley and Ian G. Mills and David J. Elliott},
  journal={Nature Reviews Urology},
  year={2016},
  volume={13},
  pages={324-333}
}
Prostate cancer is a unique and heterogeneous disease. Currently, a major unmet clinical need exists to develop biomarkers that enable indolent disease to be distinguished from aggressive disease. The prostate is an abundant secretor of glycoproteins of all types, and alterations in glycans are, therefore, attractive as potential biomarkers and therapeutic targets. Despite progress over the past decade in profiling the genome and proteome, the prostate cancer glycoproteome remains relatively… 

Glycosylation: Rising Potential for Prostate Cancer Evaluation

A review of studies evaluating the prostate cancer associated glycosylation related alterations in sialylation, mainly α2,3-sialylations, core fucosylation), branched N-glycans, LacdiNAc group and presence of truncated O- glycans discusses the great potential to make use of glycans as diagnostic and prognostic biomarkers for prostate cancer.

Glycosylation is a global target for androgen control in prostate cancer cells.

The results suggest that alterations in patterns of glycosylation via androgen control might modify some or all of these processes in prostate cancer.

The expression and functional analysis of the sialyl-T antigen in prostate cancer

Analysis of the O -glycan profiles of prostate cancer cells metastasized to bone (PC-3), brain (DU145), lymph node (LNCaP), and vertebra (VCaP) in comparison to immortalized RWPE-1 cells derived from normal prostatic tissue indicated that sialyl-3T can serve as a biomarker for metastatic prostate cancer prognosis and ST3Gal-I could be a target for therapeutic intervention in cancer treatment.

Sweet Strategies in Prostate Cancer Biomarker Research: Focus on a Prostate Specific Antigen

Various bioassay strategies for glycoprofiling of a prostate-specific antigen (PSA) with emphasis to modern and prospective techniques suitable for analysis of PSA glycan motifs as biosensors, biochips and mass spectrometry methods are focused on.

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

The authors discuss the emerging roles of galectins in prostate and bladder cancer development and progression and speculate regarding opportunities for clinical translation.

An N-glycoproteomics Analysis Reveals Glycoprotein Alterations in Esophageal Squamous Cell Carcinoma

Specific changes in the expression of glycoproteins or glycosylation occupancy have the potential to be used as the biomarker to discriminate ESCC from normal tissues and to improve the understanding of ESCC biology.

Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer

This study demonstrates that membrane-proximal N-linked glycosylation is critical for maintaining the ligand dependence of the receptor and expands the repertoire of potently oncogenic mutations in CSF3R that are therapeutically targetable.

Targeting Aberrant Sialylation to Treat Cancer

Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value.

Aberrant Sialic Acid Expression and Its Role In Regulating Metastasis in Colorectal Cancer

This review will focus on the metastatic cascade as it relates to cancer as a whole, the role of sialic acids in the metastasis cascade and the models that are available to study sIALic acid expression and how they can be applied to the study of colorectal cancer.

An N-glycoproteomic site-mapping analysis reveals glycoprotein alterations in esophageal squamous cell carcinoma

The typical changes in glycoprotein expression and glycosylation occupancy identified in this study will not only be used as ESCC biomarkers but also improve the understanding of ESCC biology.
...

References

SHOWING 1-10 OF 126 REFERENCES

Altered glycosylation in prostate cancer.

Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation*

Comparison of LNCaP and PC3 prostate cancer cell lines using integrated global proteomics and glycoproteomics shows altered protein fucosylation forms have great potential in aiding the understanding of castration resistance and may lead to the development of novel therapeutic approaches and specific detection strategies for prostate cancer.

Glycosylation in cancer: mechanisms and clinical implications

The roles of glycans are highlighted by the fact that alterations in glycosylation regulate the development and progression of cancer, serving as important biomarkers and providing a set of specific targets for therapeutic intervention.

Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer.

FUT8 may be associated with aggressive PCa and thus is potentially useful for its prognosis, and using PC3 and LNCaP cells as models, it is found that FUT8 overexpression in LNCAP cells increased PCa cell migration, while loss of F UT8 in PC3 cells decreased cell motility.

UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation

An enzyme, UAP1, is identified, which is highly overexpressed in prostate cancer and protects cancer cells from ER stress conferring a growth advantage.

N-glycan Cryptic Antigens as Active Immunological Targets in Prostate Cancer Patients

  • Denong Wang
  • Biology, Medicine
    Journal of proteomics & bioinformatics
  • 2012
Although tumor-associated abnormal glycosylation has been recognized for decades, information regarding host recognition of the evolving tumor glycome remains elusive. We report here a carbohydrate

Critical Role of O-Linked β-N-Acetylglucosamine Transferase in Prostate Cancer Invasion, Angiogenesis, and Metastasis*

The data suggest that as prostate cancer cells alter glucose and glutamine levels, O-GlcNAc modifications and OGT levels become elevated and are required for regulation of malignant properties, implicating OGT as a novel therapeutic target in the treatment of cancer.

O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.

It is reported that the HBP is activated in prostate cancer cells and that OGT is a central regulator of c-Myc stability in this setting and that c-MYC is a key target of OGT function in prostatecancer cells.

Aberrant PSA glycosylation—a sweet predictor of prostate cancer

Research has focused on the potential role of altered PSA glycosylation patterns in discriminating between significant and insignificant prostate cancers, with the aim of developing a more reliable diagnostic tool than the current serum PSA test.

Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity

The results strongly suggest that C2GnT-expressing prostate cancer cells evade NK cell immunity and survive longer in the host blood circulation, thereby resulting in the promotion of prostate cancer metastasis.
...